Your browser doesn't support javascript.
loading
Predictive and Prognostic 18F-Fluorocholine PET/CT Radiomics Nomogram in Patients with Castration-Resistant Prostate Cancer with Bone Metastases Treated with 223Ra.
Cruz-Montijano, Marcos; Amo-Salas, Mariano; Cassinello-Espinosa, Javier; García-Carbonero, Iciar; Villa-Guzman, Jose Carlos; Garcia-Vicente, Ana Maria.
Afiliación
  • Cruz-Montijano M; Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.
  • Amo-Salas M; Mathematics Department, Universidad de Castilla-La Mancha, 13071 Ciudad Real, Spain.
  • Cassinello-Espinosa J; Oncology Department, University Hospital of Guadalajara, 19002 Guadalajara, Spain.
  • García-Carbonero I; Oncology Department, University Hospital of Toledo, 45007 Toledo, Spain.
  • Villa-Guzman JC; Oncology Department, University Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
  • Garcia-Vicente AM; Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain.
Cancers (Basel) ; 16(15)2024 Jul 29.
Article en En | MEDLINE | ID: mdl-39123422
ABSTRACT

PURPOSE:

We aimed to develop a nomogram able to predict treatment failure, skeletal events, and overall survival (OS) in patients with castration-resistant prostate cancer with bone metastases (CRPC-BM) treated with Radium-223 dichloride (223Ra). PATIENTS AND

METHODS:

Patients from the Castilla-La Mancha Spanish region were prospectively included in the ChoPET-Rad multicenter study from January 2015 to December 2022. Patients underwent baseline, interim, and end-of-treatment bone scintigraphy (BS) and 18F-Fluorocholine PET/CT (FCH PET/CT) scans, obtaining multiple imaging radiomics as well as clinical and biochemical variables during follow-up and studying their association with the previously defined end-points. Survival analysis was performed using the Kaplan-Meier method and Cox regression. Multivariate logistic and Cox regression models were calculated, and these models were depicted by means of nomograms.

RESULTS:

Median progression-free survival (PFS) and OS were 4 and 14 months (mo), respectively. The variables that showed independent and significant association with therapeutic failure were baseline alkaline phosphatase (AP) levels (p = 0.022) and the characteristics of BM on the CT portion of PET/CT (p = 0.017). In the case of OS, the significant variables were therapeutic failure (p = 0.038), the number of lines received after 223Ra (p < 0.001), average SUVmax (p = 0.002), bone marrow infiltration in FCH PET/CT (p = 0.006), and interim FCH PET/CT response (p = 0.048). Final nomograms included these variables, showing good discrimination among the 100 patients included in our study. In the study of skeletal events, only OS showed a significant association in the multivariate analysis, resulting in an inconsistent nomogram design.

CONCLUSIONS:

FCH PET/CT appears to be a good tool for evaluating patients eligible for treatment with 223Ra, as well as for their follow-up. Thus, findings derived from it, such as the morphological characteristics of BM in the CT, bone marrow infiltration, or the response to 223Ra in the interim study, have proven to be solid and useful variables in the creation of nomograms for predicting therapeutic failure and OS.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: España
...